

Awards Ceremony and Closing Comments

Carole Hudgings, PhD
National Institutes of Health, NIAIDS

Sharon Hillier, PhD
University of Pittsburgh





Greatest Numbers of Accepted Abstracts for M2010

Durban MRC Team

Most Abstracts M2010: Runner-Up

Lusaka Zambia team

MTN Achievement Award 2010

- MTN-002 Team
- Richard Beigi, Protocol Chair
- Ingrid Macio, Study Coordinator
- Lisa Noguchi, CORE
- Sharon Riddler, CRS leader

Home Away From Home Awards

- Karen Patterson, SCHARP
- Kaila Gomez, FHI
- Katie Bunge, CORE
- Jeanna Piper, NIAID

Meeting Closing

- Please complete your meeting evaluations
- Mark your calendars for the M2010 meeting in Pittsburgh, PA May 22-25, 2010.
- Africa based investigators, mark your calendars for the MTN regional meeting October 4-7, 2010, Cape Town, South Africa

What Have We Learned at This Meeting?

- The differences between MDP-301 and HPTN-035
- That VOICE is now open at 11 sites, and enrollment is going well
- The future will require us to think about combining multiple interventions into a “prevention package”- but how we implement those prevention packages will require that we know our local epidemics
- The standard of care in prevention trials will change in response to emerging data and the availability of new interventions



What Have We Learned at This Meeting?

- That once we have established that a microbicide or PrEP is effective in a clinical trial, there is much to be done to ensure that the product has a public health impact- is it time for the MTN to develop a focus on access?
- Communication about HIV prevention is as difficult as doing the studies- we must continue our work so that MTN investigators and community members can communicate clinical trial results in their communities
- Once we have a microbicide or new prevention technology it will have to be marketed- we need to begin thinking of this now



What Have We Learned at This Meeting?

- HIV is a wily foe- there are reasons why it is has been difficult to find an HIV prevention product
- It is possible to use pieces of tissue in the lab to evaluate product safety, drug penetration and activity against HIV. This helps us select the most promising products to move forward
- We are learning more about how to measure levels of drug in the female genital tract, and are beginning to better understand how vaginal gels deliver drugs in a way that could block HIV
- Innovative research is helping us understand the impact of products on the gut mucosa



What Have We Learned at This Meeting?

- The NIH continues to fund developmental research which contributes new products and science into the MTN
- We will be partnering with the IPM and CONRAD on new ways to deliver ARV microbicides including rings, films and other alternative formulations



Final Words Annual Meeting 2010

- Thanks for coming.
- Remember that as we climb the mountain of HIV prevention

We can *lean* on each other

We can *learn* from each other

As long as we remember to *love* each other

And remember to *laugh* together at least once every day

HIV prevention is in our hands